Puma Begins Phase II Trial Of Neratinib In Solid Tumors With HER2 Mutation

(RTTNews) - Puma Biotechnology, Inc.(PBYI) Friday said it initiated a Phase II clinical trial or basket study of its lead drug candidate PB272 or neratinib, as a single agent in patients with solid tumors who have an activating HER2 mutation. The study is designed to assess safety and efficacy of the drug candidate.

The Phase II basket trial will at first include 6 cohorts of patients with bladder/urinary tract cancer, colorectal cancer, endometrial cancer, gastric/esophageal cancer, ovarian cancer and all other solid tumors. Each basket will comprise of 7 patients, the company said.

Puma expects to expand the trial with additional patients and additional cohorts on obtaining indication of efficacy.